Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report-MedSci.cn

Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

Wang, BY; Zhao, WH; Chen, YX; Cao, XM; Yang, Y; Zhang, YL; Wang, FX; Zhang, PY; Lei, B; Gu, LF; Wang, JL; Bai, J; Xu, Y; Wang, XG; Zhang, RL; Wei, LL; Zhuang, QC; Fan, F; Zhang, WG; He, AL; Liu, J

Liu, J (通讯作者)，Xi An Jiao Tong Univ, Dept Hematol, Affiliated Hosp 2, 157 Xiwu Rd, Xian 710004, Peoples R China.

Abstract

BackgroundMultiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Mu......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

科室

工具

服务